Home care is increasingly critical in managing hidradenitis suppurativa (HS), as patients seek convenient, non-invasive solutions to reduce flare-ups and improve daily life. From advanced topical creams to wearable compression devices, these tools are not only enhancing care but also driving demand in the HS market, which is expanding to include patient-centric, at-home solutions.

Topical therapies dominate home care. Newer formulations, like nanoemulsion-based creams that penetrate deeper into skin layers, reduce inflammation by 40% compared to traditional ointments (2026 Dermatology Research). Wearable devices, such as smart compression bands that monitor temperature and pressure, alert users to early lesion development, enabling proactive intervention. A 2023 pilot in Australia showed these bands cut severe flare-ups by 25%, boosting patient satisfaction. To gauge home care trends, stakeholders refer to Market Research Future’s report section on HS Home Care Solutions, which analyzes product launches and adoption rates.

Market demand for home care is rising. With HS impacting daily activities (e.g., clothing choice, mobility), patients prioritize convenience. In 2023, home care products accounted for 28% of HS market sales, up from 15% in 2020, driven by telehealth expansion and direct-to-consumer (DTC) marketing. Firms like DermalCare launched DTC nanoemulsion creams in 2024, reaching 50% more patients than traditional clinic sales.

Challenges include ensuring product safety and efficacy without clinical supervision. A 2026 survey found 30% of patients misapplied topical drugs, leading to skin irritation. However, manufacturer-led tutorials and app-based guidance are addressing this, improving correct usage by 40%. As HS patients seek autonomy, home care solutions are poised to grow, capturing 40% of the market by 2028 (Market Research Future). This trend not only benefits patients but also opens new revenue streams for the HS market.